Initial Hep C Data on ACH-2928 Is Encouraging | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Tibotec and Bristol-Myers Team Up to Battle Hepatitis C

Back to News Homepage
Next

Biotron's BIT225 Shows Strong Hep C Antiviral Activity

Initial Hep C Data on ACH-2928 Is Encouraging

The Editors at Hepatitis Central
December 7, 2011

Print this page

Achillion’s Phase 1b Hepatitis C trial for ACH-2928, their first generation inhibitor of the NS5A protein, posted good antiviral activity, safety and tolerability results after just three days.

Achillion Announces Preliminary Phase 1b Proof-of-Concept Data With ACH-2928 NS5A Inhibitor for the Treatment of Hepatitis C Achieves 3.68 Log10 Reduction in HCV RNA After Three Days of Treatment

NEW HAVEN, Conn., Dec 5, 2011 (GlobeNewswire via COMTEX) — Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported proof-of-concept data from its Phase 1b clinical trial of ACH-2928, a first-generation NS5A inhibitor, demonstrating that patients treated with ACH-2928 achieved a mean maximum 3.68 log10 reduction in HCV RNA after three-day monotherapy of 60 mg once daily. The compound also demonstrated good safety and tolerability both in healthy volunteers and in patients with chronic hepatitis C (HCV).

ACH-2928, Achillion’s first generation inhibitor of the NS5A protein, was discovered through the Company’s NS5A inhibitor program. Achillion also recently nominated a second-generation NS5A inhibitor, ACH-3102, which is currently undergoing IND-enabling studies and is expected to be advanced into clinical trials during the first half of 2012.
Continue reading this entire article:

http://www.marketwatch.com/story/achillion-announces-preliminary-phase-1b-proof-of-concept-data-with-ach-2928-ns5a-inhibitor-for-the-treatment-of-hepatitis-c-2011-12-05

No Comments - be the first!
Share
Share
Previous

Tibotec and Bristol-Myers Team Up to Battle Hepatitis C

Back to News Homepage
Next

Biotron's BIT225 Shows Strong Hep C Antiviral Activity

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.